These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7888107)

  • 1. Heterogeneity of Alzheimer's disease. An interpretive review.
    Fudenberg HH
    Mol Neurobiol; 1994; 9(1-3):55-71. PubMed ID: 7888107
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of therapeutic response to long-term treatment with lecithin versus piracetam plus lecithin in patients with Alzheimer's disease.
    Smith RC; Vroulis G; Johnson R; Morgan R
    Psychopharmacol Bull; 1984; 20(3):542-5. PubMed ID: 6433396
    [No Abstract]   [Full Text] [Related]  

  • 3. Piracetam combined with lecithin in the treatment of Alzheimer's disease.
    Growdon JH; Corkin S; Huff FJ; Rosen TJ
    Neurobiol Aging; 1986; 7(4):269-76. PubMed ID: 3528889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lecithin and piracetam in Alzheimer's disease.
    Davidson M; Mohs RC; Hollander E; Zemishlany Z; Powchik P; Ryan T; Davis KL
    Biol Psychiatry; 1987 Jan; 22(1):112-4. PubMed ID: 3790634
    [No Abstract]   [Full Text] [Related]  

  • 5. Levetiracetam for agitated Alzheimer's disease patients.
    Weiner MF; Womack KB; Martin-Cook K; Svetlik DA; Hynan LS
    Int Psychogeriatr; 2005 Jun; 17(2):327-8. PubMed ID: 16050441
    [No Abstract]   [Full Text] [Related]  

  • 6. Piracetam plus lecithin trials in senile dementia of the Alzheimer type.
    Samorajski T; Vroulis GA; Smith RC
    Ann N Y Acad Sci; 1985; 444():478-81. PubMed ID: 3893273
    [No Abstract]   [Full Text] [Related]  

  • 7. Levetiracetam for manic behavior in hospitalized geriatric patients with dementia of the Alzheimer's type.
    Kyomen HH; Whitfield TH; Baldessarini RJ
    J Clin Psychopharmacol; 2007 Aug; 27(4):408-10. PubMed ID: 17632234
    [No Abstract]   [Full Text] [Related]  

  • 8. [Nootropic drugs: effects and effectiveness. A reflection exemplified by a phase III study using piracetam].
    Herrmann WM; Kern U
    Nervenarzt; 1987 Jun; 58(6):358-64. PubMed ID: 3302738
    [No Abstract]   [Full Text] [Related]  

  • 9. [Alzheimer's disease therapy--theory and practice].
    Gabryelewicz T; Barcikowska M; Jarczewska DL
    Wiad Lek; 2005; 58(9-10):528-35. PubMed ID: 16529064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ginkgo biloba extract EGb 761(R), donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: a randomised, double-blind, exploratory trial.
    Yancheva S; Ihl R; Nikolova G; Panayotov P; Schlaefke S; Hoerr R;
    Aging Ment Health; 2009 Mar; 13(2):183-90. PubMed ID: 19347685
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of piracetam on cerebral glucose metabolism in Alzheimer's disease as measured by positron emission tomography.
    Heiss WD; Hebold I; Klinkhammer P; Ziffling P; Szelies B; Pawlik G; Herholz K
    J Cereb Blood Flow Metab; 1988 Aug; 8(4):613-7. PubMed ID: 3260597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Piracetam, nimodipine and tacrine in the pharmacologic treatment of dementia: bibliographic review].
    Ojer Tsakiridu D; Dosantos Hernández JO; Larrabe Medina J; Sánchez Casado JI; Sologuren Echenagusia A
    Aten Primaria; 1996 Sep; 18(5):257-60, 262-4. PubMed ID: 8936720
    [No Abstract]   [Full Text] [Related]  

  • 13. [Immunological aspects of the treatment of various forms of Alzheimer's disease].
    Leszek J; Kowal-Gierczak B
    Psychiatr Pol; 1989; 23(5-6):373-8. PubMed ID: 2562036
    [No Abstract]   [Full Text] [Related]  

  • 14. [Cognitive enhancement effect of piracetam in patients with mild cognitive impairment and dementia].
    Tariska P; Paksy A
    Orv Hetil; 2000 May; 141(22):1189-93. PubMed ID: 10853348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The use of galantamine in Alzheimer's disease associated with vascular dementia (according to the study of T. Erkinjuntti group)].
    Damulin IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2009; 109(5):65-7. PubMed ID: 19938276
    [No Abstract]   [Full Text] [Related]  

  • 16. Can the pattern of neuropsychological improvement obtained with cholinergic drugs be used to infer a cholinergic mechanism in other nootropic drugs?
    Gainotti G; Nocentini U; Sena E
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13 Suppl():S47-59. PubMed ID: 2694229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Approved drugs are to be studied for use in Alzheimer's disease.
    Hopkins Tanne J
    BMJ; 2016 Sep; 354():i5063. PubMed ID: 27644990
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effectiveness of piracetam in tardive dyskinesia - double-blind cross-over controlled trial with a placebo].
    Kabes J; Sikora J; Starý O; Pisvejc J; Hanzlícek L
    Cesk Psychiatr; 1983 Oct; 79(5):339-45. PubMed ID: 6357509
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical evaluation of compounds for the treatment of memory dysfunction.
    Growdon JH; Corkin S; Huff FJ
    Ann N Y Acad Sci; 1985; 444():437-49. PubMed ID: 3893272
    [No Abstract]   [Full Text] [Related]  

  • 20. The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease.
    Rockwood K; Fay S; Gorman M
    Int J Geriatr Psychiatry; 2010 Feb; 25(2):191-201. PubMed ID: 19548273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.